Evommune, Inc. (EVMN)

NYQ – Real vaqt narxi. Valyuta: USD

25.18

+1.05 (4.35%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

25.17

-0.01 (-0.04%)

Bozordan keyin: Jun 26, 2026, 6:40 PM EDT

07.05.2026

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across our broad chronic inflammation targeted pipeline and remain on track to deliver top-line Phase 2b data for.

14.04.2026

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

06.04.2026

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET). The event will include presentations from members of.

10.03.2026

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than 55% so far this year.

05.03.2026

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The positive top-line Phase 2a data for EVO301 marks an important milestone for Evommune and further validates IL-18 inhibition as a co.

13.02.2026

Evommune Announces $125 Million Private Placement

PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of.

12.02.2026

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Evommune, Inc. (NASDAQ: EVMN) shares are trading lower on Thursday on profit-taking after the stock soared around 70% on Wednesday.

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Evommune, Inc. (EVMN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evommune, Inc. (EVMN)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Videolar

No Data

Press-relizlar

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Videolar

No Data

Press-relizlar

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Search stocks

Evommune, Inc. (EVMN)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Evommune, Inc. (EVMN)

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Videolar

No Data

Press-relizlar

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist in Migraine Prevention Transcript

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement

Evommune Stock Cools Off After Big Rally On Successful Eczema Trial

Videolar

No Data

Press-relizlar

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights

Evommune Announces $125 Million Private Placement